Takeda buys US drug-developer Syrxx

By Renate Krelle
Friday, 11 February, 2005

Japanese pharmaceutical giant Takeda has paid US$270 million in cash to acquire Syrxx, a private drug-development company based in San Diego.

Syrxx is a specialist in high-throughput X-ray crystallography, which it uses to design therapeutics to treat metabolic diseases, cancer, and inflammation. It has several compounds for type 2 diabetes in preclinical and early clinical trials.

Takeda is under pressure to use its cash balance of over 1 trillion yen to fill its poor drug development pipeline. It halted development of a promising diabetes drug late last year.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd